SightGlass Vision DOT Lens
The SightGlass Vision DOT 0.2 lens can be considered a first-line treatment for myopia in children, with one-year randomized controlled trial data published, showing robust myopia control efficacy. They are underpinned by a different mechanism and theory of myopia control than other designs - based on contrast theory rather than optical defocus theory. The DOT 0.2 lens incorporate incorporate Diffusion Optics Technology (DOT™): thousands of microscopic light scattering elements (microdots), each about one tenth of a millimetre wide. The microdots are not designed to produce peripheral defocus - they are designed to mimic more natural contrast while providing clinically equivalent visual experience to single vision lenses. DOT spectacle lenses manage contrast by softly scattering light before it hits the retina, and before the retina detects artificial contrast and signals the eye to elongate.
Visit the SightGlass Vision DOT Lens website.
SightGlass Vision DOT Lens Information
DOT lenses are currently not available in the US but are available in selected countries outside the US.
SightGlass Vision DOT Lens articles in Myopia Profile
SightGlass Vision resources
Diffusion Optics Technology - The Mechanism of Action
Diffusion Optics Technology™ is a new and unique lens technology designs to mimic more natural contrast to help slow down axial elongation to control and reduce myopia progression. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light scattering elements called dots designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children.
SightGlass Vision and Diffusion Optics Technology
Learn more about Diffusion Optics Technology at the SightGlass Vision website.